[-] Show simple item record

dc.contributor.authorRichmond, John R.
dc.contributor.authorBabcock, Chad F.
dc.contributor.authorMayo, Helen G.
dc.date.issued2004-06eng
dc.description.abstractBoth β2-agonists and anticholinergics appear to improve symptoms for patients with chronic obstructive pulmonary disease (COPD). Recent research indicates that adding a long-acting anti-cholinergic to a β2-agonist may improve quality of life for patients with stable COPD more than the use of β2-agonists alone. Both drug classes increase exercise capacity and alleviate symptoms of COPD, although neither alters disease progression (strength of recommendation [SOR]: A). Combination therapy can lead to greater improvements in forced expiratory volume in 1 second (FEV1) than either drug alone (SOR: A). However, until recently there were no convincing direct head-to-head comparisons of the 2 classes, and it is unclear whether this difference is clinically significant.en
dc.identifier.citationJournal of Family Practice, 53(6) 2004: 494-496.en
dc.identifier.urihttp://hdl.handle.net/10355/3016
dc.publisherFamily Physicians Inquiries Networken
dc.relation.ispartofClinical Inquiries, 2004 (MU)en
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network
dc.subjectdisease progressionen
dc.subjectquality of lifeen
dc.subjectchronic obstructive pulmonary disease (COPD)en
dc.subjectcombination therapyen
dc.subject.lcshLungs -- Diseases, Obstructiveen
dc.subject.lcshPulmonary Disease, Chronic Obstructiveen
dc.subject.lcshAdrenergic beta agonistsen
dc.titleAre beta-2-agonists or anticholinergics more effective for treating COPD?en
dc.typeArticleen


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record